Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (331-340 of 440) with videos related to

Pageof 44
Sort By:
Blood Cancer Journal|August 4, 2022
Venetoclax ex vivo functional profiling predicts improved progression-free survivalVikas A Gupta, Shannon M Matulis, Benjamin G Barwick, et al.
Science Signaling|November 19, 2009
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growthTaro Hitosugi, Sumin Kang, Matthew G Vander Heiden, et al.
British Journal of Haematology|July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growthMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Blood|September 29, 2012
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneDavid I Lichter, Hadi Danaee, Michael D Pickard, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell AnalysesMeixue Duan, Doan C Nguyen, Chester J Joyner, et al.
Biomaterials|December 22, 2024
Multi-niche human bone marrow on-a-chip for studying the interactions of adoptive CAR-T cell therapies with multiple myelomaDelta Ghoshal, Ingrid Petersen, Rachel Ringquist, et al.
Ejhaem|November 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trialPaul G Richardson, Thierry Facon, Christopher P Venner, et al.
Blood Cancer Discovery|November 7, 2023
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple MyelomaPaola Neri, Benjamin G Barwick, David Jung, et al.
British Journal of Haematology|January 28, 2009
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelinePaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Cell Reports|June 25, 2023
Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analysesMeixue Duan, Doan C Nguyen, Chester J Joyner, et al.
Pageof 44

Showing results (331-340 of 440) with videos related to

Sort By:
Pageof 44
Blood Cancer Journal|August 4, 2022
Venetoclax ex vivo functional profiling predicts improved progression-free survivalVikas A Gupta, Shannon M Matulis, Benjamin G Barwick, et al.
Science Signaling|November 19, 2009
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growthTaro Hitosugi, Sumin Kang, Matthew G Vander Heiden, et al.
British Journal of Haematology|July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growthMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Blood|September 29, 2012
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneDavid I Lichter, Hadi Danaee, Michael D Pickard, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell AnalysesMeixue Duan, Doan C Nguyen, Chester J Joyner, et al.
Biomaterials|December 22, 2024
Multi-niche human bone marrow on-a-chip for studying the interactions of adoptive CAR-T cell therapies with multiple myelomaDelta Ghoshal, Ingrid Petersen, Rachel Ringquist, et al.
Ejhaem|November 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trialPaul G Richardson, Thierry Facon, Christopher P Venner, et al.
Blood Cancer Discovery|November 7, 2023
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple MyelomaPaola Neri, Benjamin G Barwick, David Jung, et al.
British Journal of Haematology|January 28, 2009
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelinePaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Cell Reports|June 25, 2023
Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analysesMeixue Duan, Doan C Nguyen, Chester J Joyner, et al.
Pageof 44